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Background: We have argued against the traditional approach of counselling avoidance of all triggers of headaches
and migraine. Problems with this approach include the impossibility of avoiding all triggers and the high costs
associated with trying to do so, and that avoidance could lead to reduced tolerance for the triggers. We
have developed an alternative approach called Learning to Cope with Triggers (LCT) that encourages avoidance
of triggers that are detrimental to health and wellbeing, but uses exposure to other triggers to desensitise
headache sufferers to the triggers. This approach has been shown to be more effective than advising avoidance of
all triggers. Trigger management is only one component of a comprehensive treatment program and the current
study is designed to evaluate a new approach to treating headaches in which LCT has been integrated into an
established cognitive-behavioural therapy (CBT) package (LCT/CBT).
Methods/Design: A target sample of 120 adult participants who suffer from migraine or tension-type headache, at
least six days per month, and have done so for at least 12 months will be recruited. Participants will be randomly
assigned to one of three groups: LCT/CBT; Avoid/CBT (CBT combined with instructions to avoid all triggers); and
waiting-list control. Measures will include: daily diaries for recording headaches, triggers and medication consumption;
headache disability and quality of life; trigger avoidance; locus of control and self-efficacy; and coping strategies.
Treatment will involve 12 60-minute sessions scheduled weekly. Assessment will be completed before and
after treatment, and at 4 and 12 month follow-up. The data will be analysed to determine which approach is
most effective, and predictors of response to treatment.
Discussion: Migraine and tension-type headache are common and can be disabling. CBT has been demonstrated
to be an efficacious treatment for both disorders. However, there is room for improvement. This study aims to increase
the efficacy of behavioural approaches and identify factors predictive of a positive response.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12614000435684.
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It has been estimated that globally, the percentage of the
adult population with an active headache disorder is
46% for headache in general, 11% for migraine, 42% for
tension-type headache, and 3% for chronic daily headache
[1]. In the World Health Organization (WHO) ranking of
causes of disability, headache disorders are in the 10 most
disabling conditions for both genders, and the 5 most dis-
abling conditions for women. Migraine has been ranked
among the diseases causing the greatest degree of handi-
cap, together with conditions such as quadriplegia, de-
mentia and active psychosis [2].
A recent large study of the triggers of migraine attacks
found 76% of migraineurs reported triggers when asked,
and this figure rose to 95% when individuals responded to
a specific list of triggers [3]. The most common headache
triggers are: (i) stress and negative emotions; (ii) sensory
triggers (flicker, glare, eyestrain, noise, odours); (iii) hun-
ger; (iv) lack of sleep or excess of sleep; (v) food (particu-
larly chocolate, cheese) and drink; (vi) alcohol; (vii)
menstruation; and (viii) weather (cold, heat, high humid-
ity) [4-6]. Many other factors have been noted including
exercise, fatigue, sexual activity, and head and neck move-
ment. A number of studies have investigated whether
migraine and tension-type headache have the same or
different triggers, and most have failed to find differences
[7-9]. Some more recent studies have found differences
with light, odours, hunger, weather and smoke being re-
ported more commonly in migraine than tension-type
headache, and head and neck movement being more com-
mon in tension-type headache [10,11].
Advice to identify and avoid triggers as a good means
of preventing headaches, has been standard practice for
decades. Researchers regularly make this point, for example,
“comprehensive migraine treatment programs emphasize
awareness and avoidance of trigger factors as part of the
therapeutic regimen” [12]. One of the ‘seven elements of
good headache management’ listed by WHO is “identi-
fication of predisposing and/or trigger factors and their
avoidance through appropriate lifestyle change” [13]. This
advice appears on numerous internet sites. For example,
the American Headache Society website includes a hand-
out entitled ‘Trigger Avoidance Information’. Headache
Apps are now available for iPhones and iPads that encour-
age trigger avoidance (e.g., iManage Migraine, Merck &
Co).
We have published three recent reviews arguing against
counselling avoidance of all headache triggers [14-16]. It is
not possible to completely avoid all potential headache
triggers as they are so diverse; and attempting to do so
could result in a restricted lifestyle [3]. It has been pointed
out that the effort to avoid every potential headache trig-
ger may itself be stressful [17]. Furthermore, advice to
avoid triggers may lead to reduced internal locus ofcontrol for headaches, with attendant adverse effects on
self-efficacy, particularly concerning perceived capacity to
cope effectively with triggers [18].
In the chronic pain literature, fear-avoidance models
have been developed, which contend that individuals
who confront their pain are considered more likely to
adaptively resume physical and social activities, whereas
those who respond to pain with anxiety and avoidance
are considered more likely to enter a self-perpetuating
vicious cycle that maintains and exacerbates pain per-
ception, leading to chronic pain and related disability
[19]. In the stress literature, it has been argued that re-
search findings indicate that coping with stress generally
takes one of two routes, avoidance or approach, and the
evidence demonstrates that the avoidance coping pathway
is not adaptive, with a few important exceptions [20]. It
has also been argued that higher levels of ‘experiential
avoidance’, a type of avoidant coping, are associated with
higher levels of general psychopathology and a lower qual-
ity of life [21].
The anxiety literature has demonstrated that short ex-
posure to anxiety-provoking stimuli results in increased
subsequent anxiety responses to the stimuli, whilst pro-
longed exposure results in decreased subsequent anxiety
responses [22]. It is short exposure, resulting from attempts
to avoid, or escape from, anxiety-eliciting situations, that
underlies the maintenance of fears and phobias. In contrast,
exposure-based approaches have been used with great suc-
cess to treat a wide range of anxiety disorders [23]. A uni-
fied treatment approach for emotional disorders which
includes preventing emotional avoidance (including be-
havioural avoidance and cognitive avoidance) and facilitat-
ing emotional exposure has been proposed [24].
A series of studies has investigated the relationship be-
tween length of exposure to various headache triggers
and the capacity of the trigger to elicit head pain. In par-
ticipants exposed to the experimentally-validated trigger
of ‘visual disturbance’ [25] for one of five durations
(‘none’, ‘very short’, ‘short’, ‘long’ and ‘very long’), nocicep-
tive response was greater for the ‘short’ exposure condi-
tion than the ‘none’ and ‘very short’ exposure conditions;
but the nociceptive response in the ‘very long’ condition
was less than in the ‘short’ condition [26]. In summary, the
results were consistent with the anxiety literature in that
short exposure increased nociceptive response whereas
very long exposure decreased nociceptive response. The
study was repeated for the validated headache triggers
of noise [27] and stress [28] with similar results. In a
study in which migraine and tension-type headache suf-
ferers attended the laboratory for six sessions of exposure
to visual disturbance, ratings of visual disturbance, negative
affect and headache intensity in response to the trigger, de-
creased from baseline by 44%, 54% and 63%, respectively,
demonstrating desensitisation [29].
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ache triggers, and the findings linking prolonged exposure
to decreased trigger potency, have led to us developing an
alternative approach to trigger management called Learn-
ing to Cope with Triggers (LCT). The word ‘cope’ is used
because of the insights that can be derived from the stress
literature which demonstrate that no single coping strategy
can be selected as the best way of coping with stress for all
situations and across time, but reviewers have concluded
that approach strategies generally are more adaptive than
avoidance strategies [30]. We have argued that similarly,
no one strategy can be singled out as the best way of man-
aging all headache triggers. Sometimes avoidance will
be the strategy of choice but more often, approach/
engagement/exposure strategies will be more effective.
Following publication of three reviews advocating the LCT
approach to trigger management, advice in the literature
is now changing [31-33]. For example, the European
Federation of Neurological Societies guidelines on the
treatment of tension-type headache include “Identification
of trigger factors should be performed, as coping with trig-
ger factors may be of value” [31].
We recently published a study designed to evaluate the
traditional advice to headache sufferers to avoid all trig-
gers (‘Avoidance’) on the one hand, and LCT that included
graduated exposure to selected triggers to promote desen-
sitisation on the other hand [34]. Individuals (84 female,
43 male) with migraine and/or tension-type headache
were assigned randomly to one of four groups: Waiting-
list (Waitlist); Avoidance; Avoidance combined with CBT
(Avoid + CBT); and LCT. Changes in headaches and medi-
cation consumption (in parentheses) from pre- to post-
treatment were (a minus sign indicates improvement):
Waitlist, +11.0% (+15.4%); Avoidance, −13.2% (−9.0%);
Avoid + CBT, −30.0% (−19.4%); and LCT, −35.9% (−27.9%).
Avoidance did not statistically differ significantly from
Waitlist on headaches or medication use, but LCT differed
significantly from Waitlist on both measures. Avoid + CBT
significantly differed from Waitlist on headaches but not
medication consumption. In summary, the study failed to
find support for the traditional approach to trigger man-
agement of advising avoidance, but LCT emerged as a
promising strategy.
Trigger management is only one aspect of a comprehen-
sive approach to the treatment of headaches. Behavioural
interventions have been shown to be quite efficacious for
the treatment of headaches. A summary of meta-analytic
reviews for behavioural treatment of migraine (thermal
biofeedback, electromyographic - EMG - biofeedback,
CBT, relaxation training) and tension-type headache
(EMG biofeedback, CBT, relaxation training) concluded
that average improvement ranged from 33% to 55%, com-
pared with 5% for no-treatment controls for migraine, and
from 35% to 55%, compared with 2% for no-treatmentcontrols for tension-type headache [35]. We evaluated our
version of CBT for migraine and tension-type headache in
a randomised controlled trial and found no differences as
a function of diagnosis [36]. CBT was associated with the
following changes: (i) average decrease in headaches of
68% post-treatment, and 77% at 12-month follow-up; and
(ii) average decrease in medication of 70% post-treatment.
The average decrease in headaches at post-treatment of
68% (95% CI, 46.44 – 89.56) compares with the range of
33% to 55% from the review [35].
This study will integrate LCT into our version of CBT
(LCT/CBT), and evaluate the efficacy of this new ap-
proach in anticipation of enhancing the effectiveness of
CBT. LCT/CBT will be compared with CBTcombined with
the standard approach to trigger management of avoid-
ance (Avoid/CBT), and with Waiting-list control (WL).
The study will test the following hypotheses:
1. LCT/CBT will result in greater decreases on the
primary outcome measures of headaches,
medication consumption and headache disability,
than Avoid/CBT and WL.
2. LCT/CBT will result in greater increases on the
secondary outcome measures of self-efficacy, internal
locus of control, and quality of life (less restricted
lifestyle), than Avoid/CBT and WL.
The study will also investigate predictors of response
to treatment and explore client-treatment matching hy-
potheses, such as whether participants who have a small
number of triggers all of which are avoidable, would re-
spond better to Avoid/CBT than LCT/CBT, whilst the re-
verse would be the case for participants who have more or
less avoidable triggers. The response of migraine versus
tension-type headache will be investigated, but there are
no specific predictions related to diagnosis as the triggers





(i) Diagnosed as either ‘migraine without aura’, ‘typical
aura with migraine headache’, ‘chronic migraine’, ‘frequent
episodic tension-type headache’, or ‘chronic tension-type
headache’; (ii) minimum of 6 headache days per month;
(iii) minimum headache chronicity of 12 months, and pat-
tern of headache symptoms stable over last six months;
(iv) medication use stable for a minimum of one month;
and (v) aged 18 to 75 years.
Exclusion criteria
(i) Diagnosed as ‘medication-overuse headache’; (ii) head-
aches present continuously; (iii) undergoing behavioural
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morbidities that are deemed likely to interfere with ability
to fully participate.
All diagnoses will be based on The International Classi-
fication of Headache Disorders, 3rd edition (beta version)
(ICHD-3 beta) [37].
Recruitment
The target sample size is 120. A range of recruitment
strategies will be used as in our previous headache re-
search including: general practitioner (GP) referrals (tar-
geting practices directly and through the Divisions of
General Practice); the media (television, community and
national newspapers, radio); posters; organisations that
have agreed to assist using their websites or newsletters
(e.g., Headache Australia, Brain Foundation); intranet
(Griffith University, Gold Coast Health); and internet, pod-
casts, YouTube and Facebook.
Research design
The design is a mixed design, consisting of a between sub-
jects factor (Group), and a within subjects factor (Time).
A computer-generated sequence will be used, and the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines followed for the randomisation procedure. The
author with statistical responsibility and no involvement
with participants (JR), will take responsibility for the ran-
domisation. The study is a single-site (university setting),
single-blind, Phase II clinical trial. The study is being con-
ducted in compliance with the Helsinki Declaration and
has been approved by the Griffith University Human
Research Ethics Committee (GU Ref No: PSY/31/13/HREC).
Written informed consent is required for all participants.
Measures
Demographic information, headache diagnosis and
functional assessment
We have developed and used in previous studies e.g., [34]
the following questionnaires to collect this background in-
formation: (i) Personal and Social History Questionnaire
(PSHQ); (ii) Headache Diagnosis Questionnaire (HDQ)
(used in conjunction with our Manual for Diagnosing
Primary Headache, based on ICHD-3 beta); and (iii)
Functional Assessment of Headache Questionnaire (FAHQ).
The PSHQ collects demographic information such as age,
gender, marital status, children, educational level, and oc-
cupation. The HDQ is a structured diagnostic interview
with questions derived directly from ICHD-3 beta. The
FAHQ includes questions about the antecedents (immedi-
ate, setting, onset and predisposing) and consequences
(immediate and long-term for sufferers and significant
others) of headaches. The PSHQ and FAHQ are derived
from the Psychological Assessment of Headache Ques-
tionnaire [38].Avoidance of headache triggers
We will use the Trigger Specific Avoidance Scale of the
Headache Triggers Avoidance Questionnaire (HTAQ)
(Wood A, Martin PR: Development of the Headache Trig-
gers Avoidance Questionnaire, in preparation). This Scale
has 24 items and measures how often respondents try
to avoid the factors that trigger their headaches. It
has good internal consistency (Cronbach alpha of .81),
good test-retest reliability over 3 to 4 weeks (r = .90,
p < .001), and construct validity shown via significant
correlations with related scales such as the Anxiety
Sensitivity Index (r = .27, p < .001) and Pain Anxiety
Symptoms Scale (r = .37, p = < .001).
Self-efficacy
The Headache Management Self-Efficacy Scale (HMSES)
consists of 25 items that inquire about an individual’s
confidence in her/his ability to prevent and to manage
headaches [39]. It has good internal consistency and
construct validity.
Locus of control
The Headache-Specific Locus of Control Scale (HSLC)
consists of 33 items for which participants indicate the
degree to which they believe that the variables control-
ling headache activity are primarily internal or external
[40]. It has three subscales (healthcare professional, in-
ternal, chance), all with good test-retest reliability and
construct validity.
Coping strategies
Coping strategies will be assessed with the Coping Strat-
egies Inventory (CSI) [41,42]. The CSI has 72 items de-
signed to assess coping strategies used in responding to
stressful life events, and includes 8 subscales, 4 for ‘en-
gagement’ strategies (e.g., social support), and 4 for ‘dis-
engagement’ strategies (e.g., avoidance). The CSI will be
included as we have found the social support subscale to
be the best predictor of response to CBT [36].
Headaches, triggers and medication
For several decades, headache diaries have been re-
corded using paper-and-pencil, but such diaries have
several important limitations including high researcher
effort and error in data entry, high percentage of partici-
pant non-compliance, and inaccurately completed and
missing items [43,44]. We have developed an e-diary
using mobile software technology that can be used on a
wide range of smartphone operating systems or installed
on Windows computers. Research has shown that com-
puterised pain diaries overcome several limitations of
paper diaries [45], and recording exact time and date of
diary completion significantly increases compliance rates
[46,47]. In accordance with recommendations on the
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seven items, which are widely considered as core ques-
tions to include in behavioural headache research [48].
The items are: current headache intensity; peak intensity;
average intensity; number of headaches; average duration
of headaches; medication consumption (number of pills
taken); and headache triggers (checklist of 26 triggers).
Participants are required to complete the e-diaries each
day just prior to going to sleep, and a paper version is
available for those who cannot use the e-diary system.
Functional status
Collecting data on measures of disability and quality of
life, as well as primary and secondary measures of head-
ache and non-headache measures (e.g., medication con-
sumption) has been recommended [49]. The functional
and emotional impact of headache on everyday life will
be measured by the Headache Disability Inventory
(HDI), and health-related quality of life by the Short-Form
Health Survey version 2 (SF-36v2). The HDI is a 25-item
questionnaire that has good internal consistency, long-
term test-retest reliability and construct validity [50].
The SF-36v2 is a 36-item questionnaire from the Medical
Outcomes Study, which measures health-related quality of




A therapist manual and client handbook were developed
for a 12-session program of 60-minute sessions sched-
uled weekly by integrating existing materials. The LCT
component of the manual specifies principles for identi-
fying triggers and deciding what strategies to use for
each trigger. For example, ‘planned exposure’ may serve
three functions: (i) exposure as an ‘experiment’ to see
if the alleged trigger does indeed precipitate headaches
(e.g., foods are often incorrectly identified as headache
triggers [51,52]); (ii) exposure to achieve desensitisation/
habituation/adaptation; and (iii) exposure to enable prac-
tising coping skills. Exposure is generally viewed as the
strategy of choice for triggers such as stress and negative
affect, and sensory triggers (e.g., visual disturbance, noise).
Avoidance is generally seen as the strategy of choice for
triggers that are not consistent with a healthy lifestyle such
as toxic smells, hunger, dehydration and lack of sleep.
Menstruation is viewed as a cue to focus on the other trig-
gers that often give rise to headaches in combination with
hormonal factors. The parameters of exposure to triggers
(length of exposure and intensity of trigger stimulus) are
always manipulated such that they fall short of precipitat-
ing significant headaches. Evidence-based strategies are
used whenever possible, such as for stress (e.g., [53]) and
anxiety (e.g., [23]).The CBT component of the program is derived from
the book Psychological Management of Chronic Head-
aches [38], and has been shown to be effective [36]. This
approach to CBT adopts a functional model that seeks
to understand the controlling variables of headaches. It
aims to answer questions such as: why does a headache
occur at one time rather than another; why is this per-
son experiencing headaches at this point in her/his life
rather than at other times; why did the headache prob-
lem begin when it did; and why is this person vulnerable
to developing a headache disorder? Functional models
consider antecedents and consequences in seeking an-
swers to these questions. As the immediate antecedents
of headaches are the triggers, LCT integrates easily into
this version of CBT. There is much overlap with CBT as
used by other research groups, such as including educa-
tion, challenging dysfunctional thoughts and beliefs, relax-
ation, pain management and relapse prevention. However,
a functional analysis might indicate, for example, that
treatment should address the setting antecedents (psycho-
social context) for headaches by focussing on the source
of stress as a trigger (e.g., dysfunctional marriage) or stress
mediating variables (e.g., deficient social support). Alter-
natively, it might indicate that maladaptive reactions to
headaches by the sufferer or their significant others should
be part of the treatment program.
Avoid/CBT
This condition is a version of the equivalent in the
MaTCH study (Avoid + CBT), extended from 8 to 12
sessions [34]. As for LCT/CBT, a therapist manual and
client handbook were developed. Sessions will be 60-
minutes each and scheduled weekly.
WL
Participants in this condition will not receive any treat-
ment until after the ‘post-treatment’ assessment period.
They will then be offered LCT/CBT or Avoid/CBT (their
choice), which will give the opportunity for further
evaluation. It will mean that these participants will be
lost to follow-up, but it is considered unethical to with-
hold treatment for a longer period.
Therapists
Therapy will be delivered by registered psychologists
who have completed postgraduate professional qualifica-
tions in clinical or counselling psychology.
Treatment integrity
Treatment fidelity (intervention actually delivered as
intended) will be assessed via a combination of thera-
pists completing checklists, and scoring 10% of videos
(randomly selected) of treatment sessions [54]. The
checking will be carried out blind to the intervention
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ment adherence (patient compliance with procedural re-
quirements) will be assessed via participants self-monitoring
[54,55]. Treatment integrity is considered particularly
important in this study as the two treatment condi-
tions overlap, with both involving CBT and even the trig-
ger management strategies not being completely different
as LCT does not involve promoting approach/engagement
strategies rather than avoidance with all triggers. A key
target in analysing treatment integrity will be document-
ing triggers for which approach/engagement versus avoid-
ance strategies are utilised.Procedure
Pre-treatment assessment and baseline self-monitoring
All individuals volunteering for the study will undergo a
telephone screening and those who meet the screening
criteria will be invited to an assessment session that
takes approximately three hours to complete. At this ses-
sion, participants will complete informed consent proce-
dures, and the HDQ. They will then complete an electronic
survey that includes the SF-36v2, HTAQ, HSLC, HDI,
HMSES, and CSI. Next, they will complete the PSHQ, and
FAHQ. Participants will then be given training in use of the
e-diaries to monitor headaches, triggers and medication
consumption. Self-monitoring will take place for four weeks
prior to the commencement of treatment.Randomisation
Participants will be randomly allocated to the three
groups in the study after the assessment session.Treatment
Participants will receive one of the three ‘treatments’
over the next 12 weeks.Post-treatment assessment
Participants will self- monitor their headaches, triggers,
and medication consumption for four weeks after treat-
ment has concluded, and then attend a psychologist,
blind to treatment condition, for a clinical assessment as
a ‘collateral’ measure of outcome. They will complete the
electronic survey with the six questionnaires embedded
in it as described above.Four- and 12-month follow-up assessments
Participants will attend a psychologist, blind to treatment
condition, 4 and 12 months after the 12-week treatment
period. They will be asked to resume self-monitoring
headaches, triggers and medication consumption for a 4-
week period, and to complete the electronic survey.Quality control
A detailed operations manual has been prepared. The
staff have all attended a 7-hour workshop training them
in the study procedures, presented by the primary inves-
tigator who has over 40 years of experience in research,
clinical practice, and training health professionals in the
headache domain. Weekly meetings will be scheduled
for the primary investigator to provide supervision for
the research staff. This will include review of ‘cases’.
Data will periodically be forwarded to the investigator
with primary responsibility for analysing the data (JR),
for review.
Statistical analyses and power considerations
The study design will focus on the interaction test of a
mixed factorial design. Data will be tested for assump-
tions underlying both univariate and multivariate para-
metric analysis.
The power analysis is based primarily on the effect
sizes generated in previous clinical trials of f = 0.33 to
0.42. Based on previous results an effect size of f = 0.25
(commonly accepted convention for a medium effect)
can be confidently predicted. Power analysis using
G*Power 3.1 software package indicates that for a three-
group mixed factorial design with 40 participants per
group and alpha = .05, moderate effects (f = .25) would
be reliably identified with power .93 and a large effect
(f = 0.4) would have an almost certain probability of
being reliably identified.
Any missing data will be considered on an intention-
to-treat basis [56,57] and fully analysed for the presence
of Missing At Random, Missing Completely At Random,
and Not Missing At Random patterns [58]. If statistically
appropriate, missing data will be imputed using case-
level multiple imputation. Data will be tested for as-
sumptions underlying both univariate and multivariate
parametric analysis. In addition to exploratory descrip-
tive and correlational analyses, group by phase factorial
ANOVAs using a Linear Mixed Models approach will be
the main method of analysis for assessing treatment out-
come. These will be supplemented by analyses of simple
main effects and trend analysis (i.e., analysis of orthog-
onal polynomials) to examine the pattern of change over
time for the experimental groups.
A linear mixed modelling approach has been chosen
in order to permit: flexible structuring of the repeated
covariance associated with the phase effect; more op-
tions for dealing with missing values; the analysis of in-
dividual change via growth curves; and options for
analysing multi-level models, should they be theoretic-
ally or clinically relevant. For all inferential tests, mea-
sures of effect size (i.e., either d or η2) will be calculated,
including confidence intervals around those measures. A
range of clinical significance measures will also be
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to examine predictors of response to treatment, and
moderation analysis will be used to examine the client-
treatment matching hypotheses [60].
Discussion
Headache disorders are among the most common disor-
ders of the nervous system, causing substantial disability
in populations throughout the world [13]. This has re-
sulted in the Global Campaign against Headache Disorders:
“Lifting the Burden”, launched jointly by WHO, Inter-
national Headache Society, World Headache Alliance and
European Headache Federation [61,62]. On 17th October
2011, in recognition of the importance of headache as a
pain disorder, the International Association for the Study of
Pain launched the Global Year Against HEADACHE Oct
2011-Oct 2012.
An extensive literature has accumulated demonstrating
that various behavioural treatments are efficacious for
both migraine and tension-type headache. The United
States Headache Consortium developed evidence-based
guidelines for the treatment of migraine based on an ex-
tensive review of the medical literature and compilation of
expert consensus, and found Grade A evidence (‘multiple
well-designed randomised clinical trials, directly relevant
to the recommendation, that yield a consistent pattern of
findings’) in support of behavioural treatments (thermal
biofeedback, EMG biofeedback, CBT and relaxation) for
migraine [63]. Nevertheless, there is room for improve-
ment of behavioural interventions.
The proposed research represents arguably the first at-
tempt to improve the efficacy of CBT for headaches. It
does so by incorporating into the approach a method of
trigger management that has been shown to be superior
to the traditional method of trigger management of en-
couraging avoidance of all triggers. The proposed research
is an efficacy trial and if the results are as predicted, then
effectiveness research should follow (how well it works in
the field).
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